Medicare Enrolled
Dr. Michael Poiesz, M.D.
Hematology & Oncology · Pensacola, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Poiesz from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Poiesz? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Poiesz
Dr. Michael Poiesz is a hematology & oncology in Pensacola, FL, with 18 years in practice. Based on federal Medicare data, Dr. Poiesz performed 115,071 Medicare services across 2,290 unique beneficiaries.
Between the years covered by Open Payments, Dr. Poiesz received a total of $3,296 from 45 pharmaceutical and/or device companies across 170 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Poiesz is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 6% volume in FL$ $3,296 industry payments
Medicare Practice Summary
Medicare Utilization ↗115,071
Medicare services
Top 6% in FL for hematology & oncology
2,290
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,393 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection (Nivestym) for white blood cells | 30,180 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 19,400 | $43 | $131 |
| Iron infusion (Feraheme) | 16,320 | $0 | $6 |
| Paclitaxel chemotherapy injection | 9,138 | $0 | $1 |
| Darbepoetin injection (Aranesp) for anemia | 9,050 | $2 | $21 |
| Contrast dye for imaging (iodine-based) | 5,600 | $0 | $3 |
| Anti-nausea injection (aprepitant) | 5,070 | $1 | $8 |
| Anti-nausea injection (fosaprepitant) | 4,200 | $0 | $6 |
| Iron infusion (Monoferric) | 3,600 | $16 | $71 |
| Denosumab injection (Prolia/Xgeva) | 2,280 | $18 | $46 |
| Immune globulin infusion (Octagam) | 1,800 | $34 | $221 |
| Office visit, established patient (30-39 min) | 1,302 | $93 | $224 |
| Dexamethasone injection (steroid) | 1,242 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia | 920 | $6 | $30 |
| Anti-nausea injection (Aloxi/palonosetron) | 890 | $1 | $122 |
| Injection, granisetron hydrochloride, 100 mcg | 580 | $0 | $25 |
| Injection of additional new drug or substance into vein | 425 | $12 | $105 |
| Injection, carboplatin, 50 mg | 372 | $2 | $300 |
| Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 372 | $93 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 281 | $100 | $686 |
| Drug injection, under skin or into muscle | 253 | $11 | $93 |
| Injection, gadobenate dimeglumine (multihance), per ml | 170 | $1 | $16 |
| Office visit, established patient (20-29 min) | 150 | $65 | $148 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 121 | $22 | $152 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 107 | $48 | $304 |
| Administration of additional new drug or substance into vein, 1 hour or less | 107 | $50 | $334 |
| New patient office visit (45-59 min) | 103 | $129 | $343 |
| Injection, diphenhydramine hcl, up to 50 mg | 98 | $1 | $5 |
| Administration of chemotherapy into vein, each additional hour | 94 | $22 | $156 |
| Office visit, established patient, complex (40-54 min) | 89 | $134 | $301 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 75 | $4 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 74 | $16 | $97 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 69 | $55 | $205 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 61 | $409 | $638 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 57 | $1,208 | $4,120 |
| Injection, zoledronic acid, 1 mg | 54 | $6 | $462 |
| Ct scan of chest with contrast | 37 | $97 | $1,005 |
| Blood creatinine level | 35 | $5 | $30 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $24 | $141 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 30 | $1 | $19 |
| Administration of additional new drug or substance into vein using push technique | 28 | $43 | $281 |
| CT scan of chest, without contrast | 25 | $83 | $861 |
| Irrigation of implanted venous access drug delivery device | 24 | $19 | $111 |
| Initial hospital admission, high complexity | 23 | $140 | $412 |
| Collection of blood sample from implanted device | 20 | $19 | $64 |
| CT scan of abdomen and pelvis with contrast | 19 | $228 | $1,400 |
| Infusion into a vein for hydration, 31-60 minutes | 19 | $25 | $249 |
| Injection of drug or substance into vein | 19 | $27 | $240 |
| Hospital follow-up visit, moderate complexity | 18 | $57 | $157 |
| Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 16 | $42 | $226 |
| Initial hospital admission, moderate complexity | 13 | $89 | $297 |
| New patient office visit, complex (60-74 min) | 11 | $138 | $432 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
19.2% high complexity
79.1% medium
1.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,296
Total received (2018-2024)
Avg $471/year across 7 years
Bottom 44% in FL for hematology & oncology
45
Companies
170
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,972 (90.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$323 (9.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$300
2023$377
2022$341
2021$231
2020$28
2019$447
2018$1,572
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$391
PFIZER INC.
$343
E.R. Squibb & Sons, L.L.C.
$259
Astellas Pharma US Inc
$255
Janssen Biotech, Inc.
$249
Ipsen Biopharmaceuticals, Inc
$234
Celgene Corporation
$112
Merck Sharp & Dohme Corporation
$101
Amgen Inc.
$92
AstraZeneca Pharmaceuticals LP
$88
GENZYME CORPORATION
$83
Genentech USA, Inc.
$81
Janssen Scientific Affairs, LLC
$79
Mirati Therapeutics, Inc.
$78
Daiichi Sankyo Inc.
$57
Pharmacyclics LLC, An AbbVie Company
$52
ABBVIE INC.
$50
Alexion Pharmaceuticals, Inc.
$47
Boston Scientific Corporation
$43
Sumitomo Pharma America, Inc.
$43
Lilly USA, LLC
$43
Regeneron Healthcare Solutions, Inc.
$39
TerSera Therapeutics LLC
$38
Myovant Sciences Inc.
$33
Boehringer Ingelheim Pharmaceuticals, Inc.
$31
Seattle Genetics, Inc.
$29
Lexicon Pharmaceuticals, Inc.
$27
Incyte Corporation
$27
Seagen Inc.
$26
CSL Behring
$26
EMD Serono, Inc.
$25
Kite Pharma, Inc.
$22
Stemline Therapeutics Inc.
$21
Tempus AI, Inc
$21
Eisai Inc.
$21
Adaptive Biotechnologies Corporation
$18
BeiGene USA, Inc.
$18
MEDIVATION FIELD SOLUTIONS LLC
$13
SpringWorks Therapeutics, Inc.
$13
R-Pharm US LLC
$13
Teva Pharmaceuticals USA, Inc.
$12
Exelixis Inc.
$12
Epizyme, Inc.,
$12
Kyowa Kirin, Inc.
$11
Janssen Pharmaceuticals, Inc
$9
Top 3 companies account for 30.1% of total payments
Associated products mentioned in payments ›
ADCETRIS · Afstyla · Aranesp · BENDEKA · BOSULIF · BRUKINSA · Balversa · Bavencio · CABLIVI · CEREZYME · CYRAMZA · Cabometyx · DARZALEX · Erleada · Fabhalta · GAUCHER-DISEASE · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Ixempra · JADENU · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · Lenvima · MEKINIST · MYLOTARG · Neulasta · OCREVUS · OGSIVEO · OPDIVO · ORGOVYX · Onivyde · Orserdu · PLUVICTO · PROMACTA · Perjeta · Pomalyst · REBLOZYL · RYDAPT · Revlimid · SANCUSO · SOLIRIS · SUTENT · Somatuline Depot · TAGRISSO · TASIGNA · TAXOTERE · TAZVERIK · TECENTRIQ · VENCLEXTA · VOTRIENT · WATCHMAN · WATCHMAN Access System · XALKORI · XT CDX · XTANDI · Xermelo · Xtandi · ZOLADEX · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (90%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
20
Per 100K population
6.2
County median income
$65,715
Nearest hospital
BAPTIST HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Poiesz is a mixed practice specialist, with above-average Medicare volume (top 6% in FL), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Poiesz experienced with filgrastim injection (nivestym) for white blood cells?
Based on Medicare claims data, Dr. Poiesz performed 30,180 filgrastim injection (nivestym) for white blood cells services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Poiesz receive payments from pharmaceutical companies?
Yes. Dr. Poiesz received a total of $3,296 from 45 companies across 170 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Poiesz's costs compare to other hematology & oncologys in Pensacola?
Dr. Poiesz's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Poiesz) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Pensacola
Browse hematology & oncologys in Pensacola ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology